Needle-Free Injection System Market Analysis and Forecast To 2031: By Product (Fillable Needle-Free Injectors, Prefilled Needle-Free Injectors), By Technology (Jet-Based Needle-Free Injectors, Spring-Based Needle-Free Injectors, Micro Array Patch Injectors), By Application (Vaccine Delivery, Insulin Delivery, Oncology, Pain Management, Dermatology), By End-Use (Hospitals, Home Care Settings, Research Laboratories, Pharmaceutical and Biotechnological Companies), And Region
The global needle-free injection system market was valued at USD 124.4 million in 2021 and it is anticipated to grow up to USD 596.9 million by 2031, at a CAGR of 17.0% during the forecast period.
Needle-free injection systems are used to administer liquid formulations, drugs, and vaccines into patients without piercing the skin with a conventional needle. The demand for these systems has increased considerably in the recent years as they improve immune response to vaccines, eliminate risks of needles, and reduce healthcare costs.
Market Trends and Drivers
High prevalence of infectious diseases globally will fuel the market growth. Despite significant improvements in sanitation and medicine, the global prevalence of infectious diseases is still high. Although non-communicable diseases are the leading causes of morbidity and mortality, infectious diseases remain a major public health concern globally. According to the National Institute of Allergy and Infectious Diseases (NIAID), annually, infectious diseases claim more than 15 million lives globally. In 2019, according to the World Malaria Report by the World Health Organization (WHO), 229 million cases of malaria occurred worldwide. The WHO African Region, with an estimated 215 million malaria cases in 2019, accounted for about 94% of the malaria cases. Similarly, as per the WHO 2021 data, there were an estimated 37.7 million people living with HIV at the end of 2020, over two-thirds of whom (25.4 million) are in the WHO African Region. The growing prevalence of chronic diseases has resulted in a significant increase in demand for biologics (large-molecule drugs). Most large-molecule drugs are administered through injectable.
Market Restraints and Challenges
Higher cost of development as compared to conventional injection systems may impede the industry growth. The overall development cost of a needle-free injection system is relatively higher due to the additional associated costs such as high infrastructural and labor costs. Development costs also increase due to the complexity of these devices. High investments in development result in a high cost of units, which decreases the adoption of these devices by patients. Sterilizable needles and conventional needle injections are the most affordable options at USD 5 to 15 for 1,000 injections. However, needle-free injections require very high initial investments and are likely to be more expensive as manufacturers are required to spend more on the production standard and quality control of the devices. The starter kits for needle-free injections themselves cost around USD 165 for AdvantaJet, USD 260 for Injex 30, and USD 300 for Medi-Jector. Owing to these high costs, affordability becomes a major issue for needle-free injection devices as compared to conventional needle injections. In addition to this, meeting all the standards and specifications makes the manufacturing process costlier than traditional injections.
Global Needle-Free Injection System Market Segmental Overview
The report analyses the global needle-free injection system market based on product, technology, application, end-use, and region.
Global Needle-Free Injection System Market by Product
Based on product, it is segmented into fillable needle-free injectors and prefilled needle-free injectors. Among these, in 2021, the fillable needle-free injectors accounted for the larger share of the needle-free injection system market. The large share of this segment can be attributed to the increasing application of needle-free injections in vaccination, insulin, and other drug delivery.
Global Needle-Free Injection System Market by Technology
Based on technology, it is segmented into jet-based needle-free injectors, spring-based needle-free injectors, and micro array patch injectors. Among them, in 2021, the jet-based needle-free injectors segment is expected to command the largest share of the global needle-free injection system devices market by technology. The large share of this segment can be attributed to benefits associated with this technology, including rapid drug administration, improved dosage accuracy, better diffusion into the tissue, and a faster response rate. For instance, NFII is a needle-free drug delivery method in which a high-speed stream of fluid impacts the skin and delivers a drug13 excluding vaccines and systemically absorbed medications like insulin.
Global Needle-Free Injection System Market by Application
Based on application, it is segmented into vaccine delivery, insulin delivery, oncology, pain management, dermatology and others. Among them, in 2021, vaccine delivery is estimated to account for the largest share of 32.8% of the needle-free injection system market by application. The rising prevalence of chronic diseases and infectious diseases worldwide has increased the demand for vaccination in the considered year and the increasing demand for patient-centric care are the major factors driving the growth of the needle-free injection market by application.
Global Needle-Free Injection System Market by End-use
Based on end-use, it is segmented into hospitals, home care settings, research laboratories, pharmaceutical and biotechnological companies and others. The hospitals & clinics segment accounted for the largest market share of 61.0% in 2020. Factors such as technological advancements and an increase in demand for vaccination are driving the growth of the hospitals & clinics segment. Other factors such as the need to improve the efficiency of diagnostic and the rising number of hospital admission will propel the market growth.
Geographical Analysis of Global Needle-Free Injection System Market
Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America accounted for significant revenue size in 2021. High awareness regarding potential benefits of needle-free drug delivery devices has supported the dominance of the region in the global arena. Moreover, presence of well-developed healthcare facilities and extensive R&D expenditure by government organizations and pharmaceutical companies for diabetes and chronic pain management are also contributing to the growth of the market.
Major Players in the Global Needle-Free Injection System Market
COVID-19 Impact
The needle-free injection system market has been positively impacted by the COVID-19 pandemic, as the need for mass vaccination needs and self-injectable devices has been the focus since the inception of the pandemic outbreak in December 2019. As the number of cases has increased across regions, most of the major needle-free injection system market players have invested in R&D and have entered into partnerships and agreements with other industry players and government agencies to develop a needle-free injection system for the disease.
About 6.8 billion COVID-19 vaccinations have been administered globally, almost double the number of routine vaccines, compared to the total manufacturing capacity of about 6 billion immunization syringes a year. As per the WHO, there could be a shortage of one to two billion syringes needed to administer COVID-19 vaccinations in 2022, which could also impact routine immunizations and undermine needle safety. This has resulted in multiple product investments and research of COVID-19 vaccine delivery devices, with surplus production and distribution of these devices across regions to serve the rising demand. Also, the increasing incidence of communicable diseases due to needlestick injuries, difficulties in vaccine storage, and needle phobia have led to their high uptake and acceptance, especially for the screening for vaccination and insulin delivery.
Recent Developments
- In March 2022, NovaXS Biotech launch injection therapy needle-free such as NovaXS Biotech wants to make injection therapy needle-free.
- In December 2021, PharmaJet partner, Nykode Therapeutics announces phase 1/2 clinical trial with next-generation DNA-based COVID-19 vaccine candidates.
- In August 2021, PharmaJet partner Zydus Cadila announced Emergency Use Authorization approval for worlds first plasmid DNA COVID-19 vaccine deliver via needle-free injection.
- In May 2021, Enesi pharma achieves key milestone in development of thermostable solid-dose live vaccines against Measles and Rubella and soon entering into clinical trials.
- In October 2020, the University of Cambridge's study of DIOSynVax's candidate was chosen to use PharmaJet's Needleless vaccine injector to inject one of the COVID-19 vaccines. The vaccine was aimed to be delivered via skin without the use of needles.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
- Chapter 1. Market Introduction
- 1.1. Objectives of The Study
- 1.2. Market Definition And Research & Scope
- 1.3. Research Methodologies
- 1.4. Market Estimation Techniques
- Chapter 2. Executive Summary
- 2.1. Summary
- 2.2. Key Highlights of The Market
- Chapter 3. Needle-Free Injection System Outlook
- 3.1. Needle-Free Injection System Segmentation
- 3.2. Market Dynamics
- 3.2.1. Market Drivers
- 3.2.1.1. Driver 1
- 3.2.1.2. Driver 2
- 3.2.1.3. Driver 3
- 3.2.2. Market Restraints
- 3.2.2.1. Restraint 1
- 3.2.2.2. Restraint 2
- 3.2.3. Market Opportunities
- 3.2.3.1. Opportunity 1
- 3.2.3.2. Opportunity 2
- 3.3. Porter’s Five Forces Analysis
- 3.3.1. Threat of New Entrants
- 3.3.2. Threat of Substitutes
- 3.3.3. Bargaining Power of Buyers
- 3.3.4. Bargaining Power of Supplier
- 3.3.5. Competitive Rivalry
- 3.4. Pestle Analysis
- 3.5. Value Chain Analysis
- 3.5.1. Raw Material Suppliers
- 3.5.2. Manufacturers
- 3.5.3. Wholesalers and/or Retailers
- 3.6. Impact of The Russia And Ukraine War on The Needle-Free Injection System
- Chapter 4. The Economic Impact of COVID-19
- 4.1. Overall Impact of COVID-19
- 4.2. Impact of COVID-19 on The Needle-Free Injection System
- 4.3. Economic Impact Analysis
- Chapter 5. Needle-Free Injection System by Product
- 5.1. Market Overview
- 5.2. Fillable needle-free injectors
- 5.2.1. Market Size And Forecast, 2021-2031 ($Million)
- 5.2.2. Market Size And Forecast, By Region, 2021-2031 ($Million)
- 5.3. Prefilled needle-free injectors
- 5.3.1. Market Size And Forecast, 2021-2031 ($Million)
- 5.3.2. Market Size And Forecast, By Region, 2021-2031 ($Million)
- Chapter 6. Needle-Free Injection System by Technology
- 6.1. Market Overview
- 6.2. Jet-based needle-free injectors
- 6.2.1. Market Size And Forecast, 2021-2031 ($Million)
- 6.2.2. Market Size And Forecast, By Region, 2021-2031 ($Million)
- 6.3. Spring-based needle-free injectors
- 6.3.1. Market Size And Forecast, 2021-2031 ($Million)
- 6.3.2. Market Size And Forecast, By Region, 2021-2031 ($Million)
- 6.4. Micro array patch injectors
- 6.4.1. Market Size And Forecast, 2021-2031 ($Million)
- 6.4.2. Market Size And Forecast, By Region, 2021-2031 ($Million)
- 6.5. Other
- 6.5.1. Market Size And Forecast, 2021-2031 ($Million)
- 6.5.2. Market Size And Forecast, By Region, 2021-2031 ($Million)
- Chapter 7. Needle-Free Injection System By Application
- 7.1. Market Overview
- 7.2. Vaccine Delivery
- 7.2.1. Market Size And Forecast, 2021-2031 ($Million)
- 7.2.2. Market Size And Forecast, By Region, 2021-2031 ($Million)
- 7.3. Insulin Delivery
- 7.3.1. Market Size And Forecast, 2021-2031 ($Million)
- 7.3.2. Market Size And Forecast, By Region, 2021-2031 ($Million)
- 7.4. Oncology
- 7.4.1. Market Size And Forecast, 2021-2031 ($Million)
- 7.4.2. Market Size And Forecast, By Region, 2021-2031 ($Million)
- 7.5. Pain Management
- 7.5.1. Market Size And Forecast, 2021-2031 ($Million)
- 7.5.2. Market Size And Forecast, By Region, 2021-2031 ($Million)
- 7.6. Dermatology
- 7.6.1. Market Size And Forecast, 2021-2031 ($Million)
- 7.6.2. Market Size And Forecast, By Region, 2021-2031 ($Million)
- 7.7. Others
- 7.7.1. Market Size And Forecast, 2021-2031 ($Million)
- 7.7.2. Market Size And Forecast, By Region, 2021-2031 ($Million)
- Chapter 8. Needle-Free Injection System By End-use
- 8.1. Market Overview
- 8.2. Hospitals
- 8.2.1. Market Size And Forecast, 2021-2031 ($Million)
- 8.2.2. Market Size And Forecast, By Region, 2021-2031 ($Million)
- 8.3. Home Care Settings
- 8.3.1. Market Size And Forecast, 2021-2031 ($Million)
- 8.3.2. Market Size And Forecast, By Region, 2021-2031 ($Million)
- 8.4. Research Laboratories
- 8.4.1. Market Size And Forecast, 2021-2031 ($Million)
- 8.4.2. Market Size And Forecast, By Region, 2021-2031 ($Million)
- 8.5. Pharmaceutical And Biotechnological Companies
- 8.5.1. Market Size And Forecast, 2021-2031 ($Million)
- 8.5.2. Market Size And Forecast, By Region, 2021-2031 ($Million)
- 8.6. Other End Users
- 8.6.1. Market Size And Forecast, 2021-2031 ($Million)
- 8.6.2. Market Size And Forecast, By Region, 2021-2031 ($Million)
- Chapter 9. Needle-Free Injection System , by Region
- 9.1. Overview
- 9.2. North America
- 9.2.1. Key Market Trends And Opportunities
- 9.2.2. North America Needle-Free Injection System Size And Forecast by Product, 2021-2031, ($Million)
- 9.2.3. North America Needle-Free Injection System Size And Forecast by Technique, 2021-2031, ($Million)
- 9.2.4. North America Needle-Free Injection System Size And Forecast by Application, 2021-2031, ($Million)
- 9.2.5. North America Needle-Free Injection System Size And Forecast by End-use, 2021-2031, ($Million)
- 9.2.6. North America Needle-Free Injection System Size And Forecast by Country, 2021-2031, ($Million)
- 9.2.7. The U.S.
- 9.2.7.1. The U.S. Needle-Free Injection System Size And Forecast by Product, 2021-2031, ($Million)
- 9.2.7.2. The U.S. Needle-Free Injection System Size And Forecast by Technique, 2021-2031, ($Million)
- 9.2.7.3. The U.S. Needle-Free Injection System Size And Forecast by Application, 2021-2031, ($Million)
- 9.2.7.4. U.S. Needle-Free Injection System Size And Forecast by End-use, 2021-2031, ($Million)
- 9.2.8. Canada
- 9.2.8.1. Canada Needle-Free Injection System Size And Forecast by Product, 2021-2031, ($Million)
- 9.2.8.2. Canada Needle-Free Injection System Size And Forecast by Technique Concentrators, 2021-2031, ($Million)
- 9.2.8.3. Canada Needle-Free Injection System Size And Forecast by Application, 2021-2031, ($Million)
- 9.2.8.4. Canada Needle-Free Injection System Size And Forecast by End-use, 2021-2031, ($Million)
- 9.2.9. Mexico
- 9.2.9.1. Mexico Needle-Free Injection System Size And Forecast by Product, 2021-2031, ($Million)
- 9.2.9.2. Mexico Needle-Free Injection System Size And Forecast by Technique, 2021-2031, ($Million)
- 9.2.9.3. Mexico Needle-Free Injection System Size And Forecast by Application, 2021-2031, ($Million)
- 9.2.9.4. Mexico Needle-Free Injection System Size And Forecast by End-use, 2021-2031, ($Million)
- 9.3. Europe
- 9.3.1. Key Market Trends And Opportunities
- 9.3.2. Europe Needle-Free Injection System Size And Forecast by Product, 2021-2031, ($Million)
- 9.3.3. Europe Needle-Free Injection System Size And Forecast by Technique, 2021-2031, ($Million)
- 9.3.4. Europe Needle-Free Injection System Size And Forecast by Application, 2021-2031, ($Million)
- 9.3.5. Europe Needle-Free Injection System Size And Forecast by End-use, 2021-2031, ($Million)
- 9.3.6. Europe Needle-Free Injection System Size And Forecast by Country, 2021-2031, ($Million)
- 9.3.6.1. Germany
- 9.3.6.2. Germany Needle-Free Injection System Size And Forecast by Product, 2021-2031, ($Million)
- 9.3.6.3. Germany Needle-Free Injection System Size And Forecast by Technique, 2021-2031, ($Million)
- 9.3.6.4. Germany Needle-Free Injection System Size And Forecast by Application, 2021-2031, ($Million)
- 9.3.6.5. Germany Needle-Free Injection System Size And Forecast by End-use, 2021-2031, ($Million)
- 9.3.7. France
- 9.3.7.1. France Needle-Free Injection System Size And Forecast by Product, 2021-2031, ($Million)
- 9.3.7.2. France Needle-Free Injection System Size And Forecast by Technique, 2021-2031, ($Million)
- 9.3.7.3. France Needle-Free Injection System Size And Forecast by Application, 2021-2031, ($Million)
- 9.3.7.4. France Needle-Free Injection System Size And Forecast by Application, 2021-2031, ($Million)
- 9.3.8. U.K
- 9.3.8.1. U.K. Needle-Free Injection System Size And Forecast by Product, 2021-2031, ($Million)
- 9.3.8.2. U.K. Needle-Free Injection System Size And Forecast by Technique, 2021-2031, ($Million)
- 9.3.8.3. U.K. Needle-Free Injection System Size And Forecast by Application, 2021-2031, ($Million)
- 9.3.8.4. U.K. Needle-Free Injection System Size And Forecast by Application, 2021-2031, ($Million)
- 9.3.9. Spain
- 9.3.9.1. Spain Needle-Free Injection System Size And Forecast by Product, 2021-2031, ($Million)
- 9.3.9.2. Spain Needle-Free Injection System Size And Forecast by Technique, 2021-2031, ($Million)
- 9.3.9.3. Spain Needle-Free Injection System Size And Forecast by Application, 2021-2031, ($Million)
- 9.3.9.4. Spain Needle-Free Injection System Size And Forecast by Application, 2021-2031, ($Million)
- 9.3.10. Italy
- 9.3.10.1. Italy Needle-Free Injection System Size And Forecast by Product, 2021-2031, ($Million)
- 9.3.10.2. Italy Needle-Free Injection System Size And Forecast by Technique, 2021-2031, ($Million)
- 9.3.10.3. Italy Needle-Free Injection System Size And Forecast by Application, 2021-2031, ($Million)
- 9.3.10.4. Italy Needle-Free Injection System Size And Forecast by Application, 2021-2031, ($Million)
- 9.3.11. Russia
- 9.3.11.1. Russia Needle-Free Injection System Size And Forecast by Product, 2021-2031, ($Million)
- 9.3.11.2. Russia Needle-Free Injection System Size And Forecast by Technique, 2021-2031, ($Million)
- 9.3.11.3. Russia Needle-Free Injection System Size And Forecast by Application, 2021-2031, ($Million)
- 9.3.11.4. Russia Needle-Free Injection System Size And Forecast by End-use, 2021-2031, ($Million)
- 9.3.12. Rest of Europe
- 9.3.12.1. Rest of Europe Needle-Free Injection System Size And Forecast by Product, 2021-2031, ($Million)
- 9.3.12.2. Rest of Europe Needle-Free Injection System Size And Forecast by Technique, 2021-2031, ($Million)
- 9.3.12.3. Rest of Europe Needle-Free Injection System Size And Forecast by Application, 2021-2031, ($Million)
- 9.3.12.4. Rest of Europe Needle-Free Injection System Size And Forecast by End-use, 2021-2031, ($Million)
- 9.4. Asia-Pacific
- 9.4.1. Key Market Trends And Opportunities
- 9.4.2. Asia-Pacific Needle-Free Injection System Size And Forecast by Country, 2021-2031, ($Million)
- 9.4.3. Asia-Pacific Needle-Free Injection System Size And Forecast by Technique, 2021-2031, ($Million)
- 9.4.4. Asia-Pacific Needle-Free Injection System Size And Forecast by Application, 2021-2031, ($Million)
- 9.4.5. China
- 9.4.5.1. China Needle-Free Injection System Size And Forecast by Product, 2021-2031, ($Million)
- 9.4.5.2. China Needle-Free Injection System Size And Forecast by Technique, 2021-2031, ($Million)
- 9.4.5.3. China Needle-Free Injection System Size And Forecast by Application, 2021-2031, ($Million)
- 9.4.5.4. China Needle-Free Injection System Size And Forecast by End-use, 2021-2031, ($Million)
- 9.4.6. India
- 9.4.6.1. India Needle-Free Injection System Size And Forecast by Product, 2021-2031, ($Million)
- 9.4.6.2. India Needle-Free Injection System Size And Forecast by Technique, 2021-2031, ($Million)
- 9.4.6.3. India Needle-Free Injection System Size And Forecast by Application, 2021-2031, ($Million)
- 9.4.6.4. India Needle-Free Injection System Size And Forecast by End-use, 2021-2031, ($Million)
- 9.4.7. Japan
- 9.4.7.1. Japan Needle-Free Injection System Size And Forecast by Product, 2021-2031, ($Million)
- 9.4.7.2. Japan Needle-Free Injection System Size And Forecast by Technique, 2021-2031, ($Million)
- 9.4.7.3. Japan Needle-Free Injection System Size And Forecast by Application, 2021-2031, ($Million)
- 9.4.7.4. Japan Needle-Free Injection System Size And Forecast by End-use, 2021-2031, ($Million)
- 9.4.8. South Korea
- 9.4.8.1. South Korea Needle-Free Injection System Size And Forecast by Product, 2021-2031, ($Million)
- 9.4.8.2. South Korea Needle-Free Injection System Size And Forecast by Technique, 2021-2031, ($Million)
- 9.4.8.3. South Korea Needle-Free Injection System Size And Forecast by Application, 2021-2031, ($Million)
- 9.4.8.4. South Korea Needle-Free Injection System Size And Forecast by End-use, 2021-2031, ($Million)
- 9.4.9. Rest of APAC
- 9.4.9.1. Rest of APAC Needle-Free Injection System Size And Forecast by Product, 2021-2031, ($Million)
- 9.4.9.2. Rest of APAC Needle-Free Injection System Size And Forecast by Technique, 2021-2031, ($Million)
- 9.4.9.3. Rest of APAC Needle-Free Injection System Size And Forecast by Application, 2021-2031, ($Million)
- 9.4.9.4. Rest of APAC Needle-Free Injection System Size And Forecast by End-use, 2021-2031, ($Million)
- 9.5. Rest of The World
- 9.5.1. Key Market Trends And Opportunities
- 9.5.2. Rest of The World Needle-Free Injection System Size And Forecast by Product, 2021-2031, ($Million)
- 9.5.3. Rest of The World Needle-Free Injection System Size And Forecast by Technique, 2021-2031, ($Million)
- 9.5.4. Rest of The World Needle-Free Injection System Size And Forecast by Application, 2021-2031, ($Million)
- 9.5.5. Rest of The World Needle-Free Injection System Size And Forecast by End-use, 2021-2031, ($Million)
- 9.5.6. Rest of The World Needle-Free Injection System Size And Forecast by Country, 2021-2031, ($Million)
- 9.5.7. Latin America
- 9.5.7.1. Latin America Needle-Free Injection System Size And Forecast by Product, 2021-2031, ($Million)
- 9.5.7.2. Latin America Needle-Free Injection System Size And Forecast by Technique, 2021-2031, ($Million)
- 9.5.7.3. Latin America Needle-Free Injection System Size And Forecast by Application, 2021-2031, ($Million)
- 9.5.7.4. Latin America Needle-Free Injection System Size And Forecast by End-use, 2021-2031, ($Million)
- 9.5.8. Middle East
- 9.5.8.1. Middle East Needle-Free Injection System Size And Forecast by Product, 2021-2031, ($Million)
- 9.5.8.2. Middle East Needle-Free Injection System Size And Forecast by Technique, 2021-2031, ($Million)
- 9.5.8.3. Middle East Needle-Free Injection System Size And Forecast by Application, 2021-2031, ($Million)
- 9.5.8.4. Middle East Needle-Free Injection System Size And Forecast by End-use, 2021-2031, ($Million)
- 9.5.9. Africa
- 9.5.9.1. Africa Needle-Free Injection System Size And Forecast by Product, 2021-2031, ($Million)
- 9.5.9.2. Africa Needle-Free Injection System Size And Forecast by Technique, 2021-2031, ($Million)
- 9.5.9.3. Africa Needle-Free Injection System Size And Forecast by Application, 2021-2031, ($Million)
- 9.5.9.4. Africa Needle-Free Injection System Size And Forecast by End-use, 2021-2031, ($Million)
- Chapter 10. Competitive Landscape
- 10.1. Market Overview
- 10.2. Market Share Analysis/Key Player Positioning
- 10.3. Developmental Strategy Benchmarking
- 10.3.1. New Testing Type Development
- 10.3.2. Chemical-based Launches
- 10.3.3. Business Expansions
- 10.3.4. Partnerships, Joint Ventures, And Collaborations
- 10.3.5. Mergers And Acquisitions
- Chapter 11. Company Profiles
- 11.1. PharmaJet (US)
- 11.1.1. Company Snapshot
- 11.1.2. Financial Performance
- 11.1.3. Chemical-based offerings
- 11.1.4. Key Strategic Initiatives
- 11.1.5. SWOT Analysis
- 11.2. Portal Instruments (US)
- 11.2.1. Company Snapshot
- 11.2.2. Financial Performance
- 11.2.3. Chemical-based offerings
- 11.2.4. Key Strategic Initiatives
- 11.2.5. SWOT Analysis
- 11.3. Medical International Technology, Inc (MIT) (US)
- 11.3.1. Company Snapshot
- 11.3.2. Financial Performance
- 11.3.3. Chemical-based offerings
- 11.3.4. Key Strategic Initiatives
- 11.3.5. SWOT Analysis
- 11.4. NuGen Medical Devices (Canada)
- 11.4.1. Company Snapshot
- 11.4.2. Financial Performance
- 11.4.3. Chemical-based offerings
- 11.4.4. Key Strategic Initiatives
- 11.4.5. SWOT Analysis
- 11.5. Crossject SA (US)
- 11.5.1. Company Snapshot
- 11.5.2. Financial Performance
- 11.5.3. Chemical-based offerings
- 11.5.4. Key Strategic Initiatives
- 11.5.5. SWOT Analysis
- 11.6. Bioject Medical Technologies (US)
- 11.6.1. Company Snapshot
- 11.6.2. Financial Performance
- 11.6.3. Chemical-based offerings
- 11.6.4. Key Strategic Initiatives
- 11.6.5. SWOT Analysis
- 11.7. Penjet.
- 11.7.1. Company Snapshot
- 11.7.2. Financial Performance
- 11.7.3. Chemical-based offerings
- 11.7.4. Key Strategic Initiatives
- 11.7.5. SWOT Analysis
- 11.8. Antares Pharma
- 11.8.1. Company Snapshot
- 11.8.2. Financial Performance
- 11.8.3. Chemical-based offerings
- 11.8.4. Key Strategic Initiatives
- 11.8.5. SWOT Analysis
- 11.9. Injex Pharma AG
- 11.9.1. Company Snapshot
- 11.9.2. Financial Performance
- 11.9.3. Chemical-based offerings
- 11.9.4. Key Strategic Initiatives
- 11.9.5. SWOT Analysis
- 11.10. Zonenix
- 11.10.1. Company Snapshot
- 11.10.2. Financial Performance
- 11.10.3. Chemical-based offerings
- 11.10.4. Key Strategic Initiatives
- 11.10.5. SWOT Analysis
- *The List of Company Is Subject To Change During The Final Compilation of The Report
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook